COVID-19 and Renin Angiotensin Blockers | Circulation www.ahajournals.org/doi/10.1161/CIRCULATIONAHA... Franz H. Messerli, MD, Swiss Cardiovascular Center, University Hospital Bern, Inselspital. ... in the form of a nasal spray to treat COVID-19. Because pneumonia is a ...
Several potential therapeutic/preventive approaches to address angiotensin-converting enzyme 2 (ACE2)-mediated COVID-19 have been described, including the suggestion that ARBs could be administered in the form of a nasal spray to treat COVID-19. Because pneumonia is a common potentially fatal complication in COVID-19 infection, we wondered whether RAS blockade could exert a favorable effect on pneumonia-related outcomes.
The differentiation of the variants was carried out using the latest sequencing technology and PCR techniques by Martin Beer's team at the Friedrich Loeffler Institute, Federal Research Institute for Animal Health, in Greifswald-Insel Riems (D). "Our study stands out because we were able to clearly discern the more efficient transmission of the mutated variant in direct comparison with the original variant," says Volker Thiel.
Similar research projects on infectious pathogens could also be carried out in the future at the newly established Multidisciplinary Center for Infectious Diseases and Immunity (MCIDI) at the University of Bern.
The study was financially supported by the Swiss National Science Foundation SNF, the European Commission, the German Federal Ministry of Education and Research, and the U.S. Department of Health & Human Services, National Institutes of Health (NIH) / Institute of Allergy and Infectious Diseases (NIAID).
News 
Market Data 
Discover 
